Deutsche Bank Aktiengesellschaft Forecasts Strong Price Appreciation for Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health (NYSE:HIMS) had its price objective increased by Deutsche Bank Aktiengesellschaft from $23.00 to $27.00 in a research report report published on Wednesday,Benzinga reports. Deutsche Bank Aktiengesellschaft currently has a hold rating on the stock.

A number of other research firms have also commented on HIMS. Truist Financial upped their price target on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, July 18th. Needham & Company LLC initiated coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price target for the company. Bank of America lifted their target price on shares of Hims & Hers Health from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Piper Sandler reissued a “neutral” rating and issued a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday. Finally, Imperial Capital cut Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Hims & Hers Health Price Performance

HIMS stock traded up $0.29 during midday trading on Wednesday, reaching $23.71. The company had a trading volume of 5,980,424 shares, compared to its average volume of 8,606,523. The firm has a 50-day moving average price of $18.40 and a 200-day moving average price of $18.29. Hims & Hers Health has a 1 year low of $6.58 and a 1 year high of $25.74. The company has a market capitalization of $5.09 billion, a P/E ratio of 54.80 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 11.67% and a net margin of 8.19%. Hims & Hers Health’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.04) earnings per share. On average, equities analysts predict that Hims & Hers Health will post 0.22 EPS for the current year.

Insider Buying and Selling

In other news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the transaction, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at $487,789.12. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the sale, the chief executive officer now owns 33,502 shares of the company’s stock, valued at approximately $487,789.12. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Soleil Boughton sold 2,339 shares of the company’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total value of $54,171.24. Following the completion of the transaction, the insider now owns 169,935 shares of the company’s stock, valued at $3,935,694.60. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 650,659 shares of company stock valued at $11,712,198. 17.71% of the stock is owned by company insiders.

Institutional Trading of Hims & Hers Health

A number of large investors have recently made changes to their positions in the business. Carnegie Investment Counsel purchased a new position in shares of Hims & Hers Health during the 3rd quarter worth about $5,531,000. International Assets Investment Management LLC purchased a new stake in shares of Hims & Hers Health in the third quarter valued at approximately $6,790,000. Sei Investments Co. lifted its holdings in shares of Hims & Hers Health by 206.9% in the 1st quarter. Sei Investments Co. now owns 56,202 shares of the company’s stock worth $869,000 after buying an additional 37,890 shares during the period. Quantbot Technologies LP increased its position in Hims & Hers Health by 3,444.9% during the 1st quarter. Quantbot Technologies LP now owns 214,677 shares of the company’s stock valued at $3,321,000 after purchasing an additional 208,621 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Hims & Hers Health by 164.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock worth $10,663,000 after buying an additional 328,142 shares during the period. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.